Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Zhang, Yuanfeng; Wu, Juanjuan; Zhao, Chaobin; Zhang, Shuyuan; Zhu, Jianbo

doi:10.7150/jca.81899

Cited by 9 publications

(4 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As PDL1+ is a dynamic biomarker whose expression is stimulated in response to IFN gamma by TILs, it can be hypothesized that PDL1+ expression simply reflects a more inflammatory tumor microenvironment. To date, no further insights have been gained from clinical trials [ 107 , 108 ]. For instance, in the Keynote 028 phase 1B multi-cohort study, which involved 24 PDL1+ patients, an ORR of 17% was observed [ 109 ].…”

Section: Role Of the Tumor Immune Microenvironment In Asccmentioning

confidence: 99%

Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances

Iseas,

Mariano,

Gros

et al. 2024

Mol Diagn Ther

View full text Add to dashboard Cite

Anal squamous cell carcinoma (ASCC) is a rare gastrointestinal malignancy associated with high-risk human papillomavirus (HPV) and is currently one of the fastest-growing causes of cancer incidence and mortality in developed countries. Although next-generation sequencing technologies (NGS) have revolutionized cancer and immuno-genomic research in various tumor types, a limited amount of clinical research has been developed to investigate the expression and the functional characterization of genomic data in ASCC. Herein, we comprehensively assess recent advancements in “omics” research, including a systematic analysis of genome-based studies, aiming to identify the most relevant ASCC cancer driver gene expressions and their associated signaling pathways. We also highlight the most significant biomarkers associated with anal cancer progression, gene expression of potential diagnostic biomarkers, expression of therapeutic drug targets, and emerging treatment opportunities. This review stresses the urgent need for developing target-specific therapies in ASCC. By illuminating the molecular characteristics and drug-target expression in ASCC, this study aims to provide insights for the development of precision medicine in anal cancer.

show abstract

Section: Role Of the Tumor Immune Microenvironment In Asccmentioning

confidence: 99%

Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances

Iseas,

Mariano,

Gros

et al. 2024

Mol Diagn Ther

View full text Add to dashboard Cite

show abstract

“…Several studies have been carried out to show that the efficacy of PD-1/PD-L1 inhibitors is positively correlated with the expression of PD-L1 protein, and different induction modalities are capable to shift the PD-L1 expression on the tumor surface, while radiotherapy is one of the effective modalities to upregulation of PD-L1 [51,52]. Schweiger and collegues have comfirmed that radiotherapy modulated the immune suppression by increasing the PD-L1 expression of macrophages to affect Glioblastoma resistance [53].…”

Section: The Aes Of Pd-1/pd-l1 Inhibitors With Radiotherapymentioning

confidence: 99%

PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

Lei,

Kong,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

As the positive results of multiple clinical trials were released, the Programmed cell death 1 (PD-1) and Programmed cell death ligand 1 (PD-L1) inhibitors emerge as the focus of integrative breast cancer treatment. PD-1/PD-L1 inhibitors are often used as a sequential agent to be combined with other agents such as chemotherapeutic agents, targeted agents, and radiation therapy. As multiple therapies are administered simultaneously or in sequence, they are prone to a variety of adverse effects on patients while achieving efficacy. It is a challenge for clinicians to maintaining the balance between immune-related adverse effects(irAEs) and treatment efficacy. Previous literatures have paid lots of attention on the adverse effects caused by immunosuppressive agents themselves, while there is a dearth of the research on the management of adverse immune effects during the combination of immunotherapy with other treatments. In this review, we discuss the overall incidence of irAEs caused by PD-1/PD-L1 inhibitors in combination with various types of treatments in breast cancer, including chemotherapy, CTLA-4 inhibitors, targeted therapy, and radiotherapy, and systematically summarizes the clinical management to each organ-related adverse immune reaction. It is important to emphasize that in the event of irAEs such as neurological, hematologic, and cardiac toxicity, there is no alternative treatment but to terminate immunotherapy. Thus, seeking more effective strategy of irAEs' management is imminent and clinicians are urged to raise the awareness of the management of adverse immune reactions.

show abstract

“…However, developing a robust preliminary assay tool that enables in situ monitoring of PD-L1 at the cellular level and offers reliable and quantitative real-time diagnostic results remains a challenge. [13][14][15][16] A variety of sensors have been explored to achieve accurate detection of disease-related biomarkers and meet the increasing demand for point-of-care medical diagnostics. The performance of sensors in terms of reproducibility, robustness, reliability, and accuracy has been the focus of significant research efforts in recent years.…”

Section: Introductionmentioning

confidence: 99%

Enhanced Electrochemical Characterization of the Immune Checkpoint Protein PD‐L1 using Aptamer‐Functionalized Magnetic Metal‐Organic Frameworks

Ma,

Wu,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Programmed death ligand 1 (PD‐L1) is highly expressed in cancer cells and participates in the immune escape process of tumor cells. However, as one of the most promising biomarkers for cancer immunotherapy monitoring, the key problem ahead of practical usage is how to effectively improve the detection sensitivity of PD‐L1. Herein, an electrochemical aptasensor for the evaluation of tumor immunotherapy is developed based on the immune checkpoint protein PD‐L1. The fundamental principle of this method involves the utilization of DNA nanotetrahedron (NTH)‐based capture probes and aptamer‐modified magnetic metal‐organic framework nanocomposites as signaling probes. A synergistic enhancement is observed in the electrocatalytic effect between Fe3O4 and UiO‐66 porous shells in Fe3O4@UiO‐66 nanocomposites. Therefore, the integration of aptamer‐modified Fe3O4@UiO‐66@Au with NTH‐assisted target immobilization as an electrochemical sensing platform can significantly enhance sensitivity and specificity for target detection. This method enables the detection of targets at concentrations as low as 7.76 pg mL−1 over a wide linear range (0.01 to 1000 ng mL−1). The authors have successfully employed this sensor for in situ characterization of PD‐L1 on the cell surface and for monitoring changes in PD‐L1 expression during drug therapy, providing a cost‐effective yet robust alternative to highly expensive and expertise‐dependent flow cytometry.

show abstract

Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy

Cited by 9 publications

References 158 publications

Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances

Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances

PD-1/PD-L1 Inhibitor - Related Adverse Events and Their Management in Breast Cancer

Enhanced Electrochemical Characterization of the Immune Checkpoint Protein PD‐L1 using Aptamer‐Functionalized Magnetic Metal‐Organic Frameworks

Contact Info

Product

Resources

About